Nicolet Advisory Services LLC Purchases 487 Shares of Humana Inc. (NYSE:HUM)

Nicolet Advisory Services LLC lifted its holdings in shares of Humana Inc. (NYSE:HUM) by 42.8% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 1,624 shares of the insurance provider’s stock after purchasing an additional 487 shares during the period. Nicolet Advisory Services LLC’s holdings in Humana were worth $437,000 as of its most recent filing with the SEC.

Other large investors have also recently modified their holdings of the company. FPC Investment Advisory Inc. purchased a new position in shares of Humana in the fourth quarter worth $27,000. Centricity Wealth Management LLC bought a new stake in shares of Humana in the fourth quarter worth about $30,000. LFA Lugano Financial Advisors SA increased its holdings in Humana by 56.3% during the 4th quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider’s stock valued at $32,000 after purchasing an additional 45 shares during the period. OFI Invest Asset Management bought a new position in Humana during the 4th quarter valued at approximately $33,000. Finally, Atwood & Palmer Inc. lifted its holdings in Humana by 64.5% in the 4th quarter. Atwood & Palmer Inc. now owns 153 shares of the insurance provider’s stock worth $39,000 after buying an additional 60 shares during the period. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Humana Stock Performance

Shares of HUM opened at $264.67 on Friday. The company has a market cap of $31.94 billion, a price-to-earnings ratio of 26.60, a P/E/G ratio of 2.05 and a beta of 0.62. The business’s fifty day simple moving average is $268.40 and its two-hundred day simple moving average is $272.56. Humana Inc. has a 12 month low of $213.31 and a 12 month high of $406.46. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.68.

Humana (NYSE:HUM) last released its quarterly earnings data on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, beating the consensus estimate of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. Research analysts anticipate that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 25th. Stockholders of record on Friday, March 28th will be issued a dividend of $0.885 per share. The ex-dividend date is Friday, March 28th. This represents a $3.54 annualized dividend and a dividend yield of 1.34%. Humana’s payout ratio is 35.58%.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on HUM. Cantor Fitzgerald reissued a “neutral” rating and set a $290.00 target price on shares of Humana in a research note on Wednesday, February 12th. Truist Financial upped their price objective on shares of Humana from $260.00 to $290.00 and gave the stock a “hold” rating in a report on Monday, January 6th. StockNews.com lowered shares of Humana from a “buy” rating to a “hold” rating in a research note on Tuesday, March 18th. Piper Sandler increased their price target on shares of Humana from $270.00 to $288.00 and gave the stock a “neutral” rating in a research note on Wednesday, January 15th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $283.00 price objective on shares of Humana in a research report on Wednesday, February 12th. Eighteen equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, Humana presently has a consensus rating of “Hold” and an average price target of $280.17.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.